Novo Nordisk moves Delhi HC to block Sun Pharma's semaglutide launch

• Novo Nordisk has filed a petition in the Delhi High Court to prevent Sun Pharma from launching its generic version of semaglutide.
• The Danish drugmaker aims to protect its market position for semaglutide, the active ingredient in its blockbuster drug Ozempic.
• Novo Nordisk holds two key semaglutide patents, with one expiring in September 2024 and the other in March 2026.
• This legal action follows a recent setback for Novo Nordisk, where Dr Reddy's Laboratories was permitted to export semaglutide generics.
• The Delhi High Court will hear Novo Nordisk's application soon, as other Indian pharma companies also eye the semaglutide market.

Why It Matters: The outcome affects access and affordability of key diabetes/obesity drugs in India.